Welcome to our dedicated page for Pulsenmore Ltd. SEC filings (Ticker: PLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulsenmore Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulsenmore Ltd.'s regulatory disclosures and financial reporting.
Pulsenmore Ltd. director Racheli Guz-Lavi filed an initial Form 3 reporting derivative holdings rather than a new trade. She holds options to purchase Ordinary Shares at an exercise price of 0.032 per share, with tranches first exercisable in 2022 and 2023 and expiring on January 5, 2028. Footnotes state these options were granted on January 5, 2021, are fully vested and exercisable, and are held through a trustee to qualify for Israeli tax benefits under Section 102.
Pulsenmore Ltd. Chief Financial Officer Eran Hirsh filed an initial ownership report showing options to purchase 7,312 Ordinary Shares. These options have an exercise price of $6.41 per share and expire on February 1, 2033. They were granted on August 14, 2024 and vest from February 1, 2027 through February 1, 2030, subject to continued service.
Pulsenmore Ltd. director Jonathan Adereth has filed an initial Form 3 reporting his ownership in the company. The filing shows that he directly holds 129,062 Ordinary Shares following the reported position. This is an ownership snapshot rather than a new share purchase or sale.
A footnote explains that, under Section 102 of the Israeli Tax Ordinance, securities issued to employees or directors in connection with the Pulsenmore Ltd. 2019 Amended Share Incentive Plan must be registered in the name of a trustee to qualify for certain tax benefits.
Pulsenmore Ltd. director Anat Loewenstein filed an initial ownership report showing holdings of options to purchase ordinary shares. The options carry an exercise price of $44.0400 per share and are scheduled to expire on August 10, 2028.
The options were granted on August 10, 2021. According to the filing, 20,508 options are already fully vested and exercisable, while 1,464 additional options vest on May 10, 2026 and 1,465 on August 10, 2026. To qualify for certain Israeli tax benefits, these securities must be registered in a trustee’s name under Pulsenmore’s 2019 Amended Share Incentive Plan.
Pulsenmore Ltd. filed an initial ownership report for its GC & Corporate Secretary, Michael Hamelsdorf, showing a derivative position in company equity. He holds options to purchase 6,093 Ordinary Shares at an exercise price of $6.4100 per share, expiring on February 1, 2033.
The options were granted on October 19, 2023 and will vest over time. According to the vesting schedule, 1,523 options vest on February 1, 2027, with the remaining options vesting in twelve equal quarterly installments from May 1, 2027 through February 1, 2030, subject to his continued service.
Pulsenmore Ltd. director Linda Messalem has filed an initial statement of beneficial ownership showing stock option holdings. She holds options to purchase Ordinary Shares with an exercise price of $44.04 per share, granted on August 10, 2021 under the company’s 2019 Amended Share Incentive Plan.
According to the footnotes, one option grant is fully vested and exercisable. For another reported grant, 20,508 options are already vested, and an additional 1,464 options vest on May 10, 2026 and 1,465 options vest on August 10, 2026. The options are held directly in her name, with certain awards registered in a trustee’s name to qualify for Israeli tax benefits.
Pulsenmore Ltd. director Itkin Hagai filed an initial insider ownership report on Form 3. This filing establishes his status as a director and subject to insider reporting rules but does not list any specific share or option holdings or report any transactions.
Pulsenmore Ltd., a foreign private issuer based in Israel, has furnished an updated corporate presentation as part of a Form 6-K report. The presentation, dated March 18, 2026, was posted on the company’s website and is attached to the report as Exhibit 99.1.
Pulsenmore Ltd. is expanding its U.S. presence through a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice in Maryland. TLC Perinatal will integrate Pulsenmore’s Early Screening home ultrasound services into a hybrid care model that blends at-home scans, telehealth, and in-clinic visits.
The practice, led by Medical Director Dr. Richard (Richie) Broth and managing about 2,000 pregnancies annually across two Maryland locations, plans to use Pulsenmore’s technology to support remote monitoring while physicians retain clinical oversight. Pulsenmore views this agreement as evidence of growing U.S. interest in patient-centric prenatal technologies following its FDA clearance.
Pulsenmore Ltd. reported its first commercial engagement with a medical center in the United States for its home pregnancy ultrasound service. This follows recent FDA clearance for the company’s home-use pregnancy ultrasound product.
On January 29, 2026, Pulsenmore, through a subsidiary, signed a services agreement with the Center for Fetal Medicine & Women’s Ultrasound, a fetal medicine and women’s ultrasound center operating from two locations in the Los Angeles area. Under this agreement, the center will purchase Pulsenmore ES home ultrasound services so pregnant patients can be remotely monitored and reduce unnecessary in-clinic diagnostic visits, with a particular focus on high-risk pregnancies.